2022
From the prodromal stage of multiple sclerosis to disease prevention
Marrie R, Allegretta M, Barcellos L, Bebo B, Calabresi P, Correale J, Davis B, De Jager P, Gasperi C, Greenbaum C, Helme A, Hemmer B, Kanellis P, Kostich W, Landsman D, Lebrun-Frenay C, Makhani N, Munger K, Okuda D, Ontaneda D, Postuma R, Quandt J, Roman S, Saidha S, Sormani M, Strum J, Valentine P, Walton C, Zackowski K, Zhao Y, Tremlett H. From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology 2022, 18: 559-572. PMID: 35840705, DOI: 10.1038/s41582-022-00686-x.Peer-Reviewed Original ResearchConceptsMultiple sclerosisTrials of interventionsType 1 diabetes mellitusImmune-mediated diseasesStandard criteriaDiagnosis of MSStages of MSDisease frameworkIdentification of individualsProdromal stageMS prodromeDisease preventionProdromal MSStop progressionRheumatoid arthritisProdromeDiseaseDisease markers
2021
The multiple sclerosis prodrome
Makhani N, Tremlett H. The multiple sclerosis prodrome. Nature Reviews Neurology 2021, 17: 515-521. PMID: 34155379, PMCID: PMC8324569, DOI: 10.1038/s41582-021-00519-3.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCognitive DysfunctionHumansMultiple SclerosisNeuroimagingProdromal SymptomsRisk FactorsConceptsMultiple sclerosisMS prodromeProdromal phaseCause of MSLong-term disabilityMultiple sclerosis prodromePutative risk factorsProfound clinical implicationsRelapse rateClinical featuresEarly recognitionInflammatory diseasesRisk factorsEarly initiationProdromePotential biomarkersClinical implicationsTypical symptomsDiseaseSymptomsFuture initiativesSclerosisMajor knowledge gapsBiomarkersPossible duration